Results 181 to 190 of about 185,884 (310)
Endotypes: a customized approach to prevent atherosclerotic cardiovascular disease
Atherosclerotic cardiovascular diseases are the first cause of death and disability in Europe. Atherosclerosis is a silent killer: it progressively infiltrates the vascular wall and suddenly becomes evident with acute and potentially deadly events, such ...
Bruna Gigante
core +1 more source
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li +12 more
wiley +1 more source
An oral microbiome model for predicting atherosclerotic cardiovascular disease. [PDF]
Sui Q, Yu J, Cui S.
europepmc +1 more source
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh +18 more
wiley +1 more source
Association between depressive symptoms and atherosclerotic cardiovascular disease: a Swedish population-based cohort study. [PDF]
Rausch C +4 more
europepmc +1 more source
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source
Association of apolipoprotein C-III with atherosclerotic cardiovascular disease and the effectiveness of simulated interventions. [PDF]
Deng X +13 more
europepmc +1 more source
Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen +7 more
wiley +1 more source
A Comprehensive, Updated Review of Ezetimibe: Evidence-Based Clinical Use for Atherosclerotic Cardiovascular Disease. [PDF]
Liu HH, Liu ZH, Chen SS, Zhu CG, Li JJ.
europepmc +1 more source
Abstract Aims Inflammation plays a critical role in both the development and progression of heart failure (HF), which is a leading cause of morbidity and mortality worldwide. However, the causality between specific inflammation‐related proteins and HF risk remains unclear.
Xian‐Guan Zhu +9 more
wiley +1 more source

